Licensing Agreement
The latest news about Licensing Agreement: headlines, AI summaries and the full story from every source.
- Fossil Raises Full-Year Sales Guidance Following Q3 Growth and Diesel License Extension
- Ocugen Outlicenses Gene Therapy Candidate OCU400 to Celairis Therapeutics for Asia-Pacific Region
- Under Armour Reports Q2 Fiscal 2027 Revenue Decline Amid Strategic Restructuring
- AbbVie and Nxera Pharma Enter $1.5 Billion Licensing Agreement for IBD Therapy
- Aquestive Therapeutics Reports Q3 2026 Results with Revenue Decline and Anaphylm Regulatory Update
- Cboe Global Markets Reports 18% Revenue Growth and Secures Long-Term S&P Licensing
- InterDigital Projects 2026 Adjusted EBITDA Between $507 Million and $515 Million
- MiMedx Enters $25 Million Patent License Agreement to Resolve Infringement Claims
- S&P Global Announces Strategic Review of Capital IQ and Raises Full-Year Profit Guidance
- WHP Global and G-III Apparel Group Partner with I.T Group to Expand Marc Jacobs in Greater China
- Delaware Jury Awards Qualcomm $2 in Damages from Arm Over License Agreement Breach
- Delaware Jury Awards Qualcomm $2, Finds Arm Breached License Agreement
- Qualcomm Says Jury Found Arm Breached License Agreement
- Axonex Robotics Signs Two-Year Deal Worth Up to €3 Million with Centridex
- Netlist shares rise after Micron agrees to pay $600 million for five-year licensing deal
- Novartis Enters Licensing Agreement with Abogen for RNA Therapeutics
- Teva and Samsung Bioepis Partner on Up to Six Biosimilars
- Merck Enters Global Licensing Agreement With SciBrunch Therapeutics
- BoomRay Pharmaceuticals Enters into $900M Deal with Novartis for Radioligand Therapy
- Vicor Raises Q3 Revenue Outlook Amid Licensing Agreement
- MannKind Collaborates with Rose Pharma on Inhaled Weight Loss Drug Amid Expanding Financial Challenges
- RedHill Acquires Commercial Rights to Rebyota and Clenpiq for $12M Upfront
- HUTCHMED Announces Major Licensing Agreement with GSK for Experimental Cancer Therapy
- Pfizer and Medicus Enter Licensing Deal Worth Up to $1 Billion for Antibody Drug Conjugate
- Gossamer Bio Shares Rise on FDA Update and Regained Rights to Seralutinib
- Jupiter Neurosciences Licenses ALA-002 from PharmAla Biotech in $100M Deal
- Jupiter Neurosciences Acquires U.S. Rights to ALA-002 for Up to $100 Million
- Kate Spade Enters Global Licensing Partnership with Movado Group for Watch Production
- Spero Therapeutics Licenses Innovent's Antibody Therapy in Deal Worth Up to $1.1 Billion
- AstraZeneca Enters $1.5 Billion License Deal for Lung Cancer Drug
- Ocugen Signs Licensing Term Sheet for OCU400 with Roots Pharmaceutical
- Kering Exits Beauty Business and Terminates Partnership With Coty
- CytomX Expands Licensing Agreement With Regeneron Pharmaceuticals
- Travere Therapeutics Enters Licensing Agreement Worth up to $1.1 Billion with Everest Medicines
- Varun Beverages Extends PepsiCo Licensing Agreement Until 2049
- Google DeepMind Agrees to Hire Researchers and License Technology from Contextual AI
- Vir Biotechnology (VIR) Reports 80.98% Year-to-Date Stock Growth
- Carlsberg Acquires Additional PepsiCo Distribution Rights in Northern Europe as Royal Unibrew Contract Expires
- EnWave Corp Secures First Commercial License in Africa Through Partnership in Egypt